RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
1.030
0.00 (0.00%)
At close: Dec 31, 2025, 4:00 PM EST
0.9601
-0.0700 (-6.79%)
After-hours: Dec 31, 2025, 7:59 PM EST
RedHill Biopharma Revenue
RedHill Biopharma had revenue of $2.04M in the half year ending June 30, 2025, with 58.59% growth. This brings the company's revenue in the last twelve months to $9.55M, up 157.62% year-over-year. In the year 2024, RedHill Biopharma had annual revenue of $8.04M with 23.17% growth.
Revenue (ttm)
$9.55M
Revenue Growth
+157.62%
P/S Ratio
0.17
Revenue / Employee
$272,857
Employees
35
Market Cap
3.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.04M | 1.51M | 23.17% |
| Dec 31, 2023 | 6.53M | -55.27M | -89.43% |
| Dec 31, 2022 | 61.80M | -23.96M | -27.94% |
| Dec 31, 2021 | 85.76M | 21.40M | 33.25% |
| Dec 31, 2020 | 64.36M | 58.07M | 923.03% |
| Dec 31, 2019 | 6.29M | -2.07M | -24.75% |
| Dec 31, 2018 | 8.36M | 4.35M | 108.63% |
| Dec 31, 2017 | 4.01M | 3.91M | 3,867.33% |
| Dec 31, 2016 | 101.00K | 98.00K | 3,266.67% |
| Dec 31, 2015 | 3.00K | -7.01M | -99.96% |
| Dec 31, 2014 | 7.01M | 7.00M | 58,350.00% |
| Dec 31, 2013 | 12.00K | -4.00K | -25.00% |
| Dec 31, 2012 | 16.00K | -7.00K | -30.43% |
| Dec 31, 2011 | 23.00K | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RDHL News
- 17 days ago - RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells - PRNewsWire
- 4 weeks ago - RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement - PRNewsWire
- 2 months ago - RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement - PRNewsWire
- 2 months ago - RedHill Biopharma Receives Nasdaq Staff Determination Notification - PRNewsWire
- 2 months ago - CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO - PRNewsWire
- 3 months ago - RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® - PRNewsWire
- 3 months ago - RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo - PRNewsWire
- 4 months ago - RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights - PRNewsWire